Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Neoplasma Vol.60, No.4, p.425-431, 2013 |
||
Title: Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC | ||
Author: O. Fiala, M. Pesek, J. Finek, L. Benesova, Z. Bortlicek, M. Minarik | ||
Abstract: Molecular targeted therapy based on EGFR tyrosine kinase inhibitors (EGFR-TKI) is currently a state of the art option for management of advanced stage NSCLC. Activating EGFR mutations are preferable for a good treatment response to EGFR-TKI. The presented retrospective study evaluated a clinical observation of EGFR-TKI aiming at its efficacy and safety in comparison to a standard chemotherapy in the first-line treatment of advanced stage NSCLC. The analysis results showed a favourable DCR and PFS in patients treated with EGFR-TKI in the first line. The non-significant difference in OS could be attributed to a cross-over during the patient follow-up as well as the differences in performance status and age between both groups. EGFR-TKI is the optimal choice for the first-line treatment of EGFR mutation-positive NSCLC. |
||
Keywords: EGFR-TKI, first-line treatment, NSCLC, erlotinib, gefitinib, targeted treatment of NSCLC | ||
Published online: 12-Apr-2013 | ||
Year: 2013, Volume: 60, Issue: 4 | Page From: 425, Page To: 431 | |
doi:10.4149/neo_2013_055 |
||
|
download file |
|